Development of a Curcumin-Based Pentraxin Conjugate for Targeted Cancer Therapy
ISEF · 2026 Biochemistry
Overview
In 2025, an estimated 2,041,910 new cases of cancer will be diagnosed in the United States, and 618,120 people will die from the disease (NIH, 2025). It is a leading cause of death worldwide, and the number is still on the rise. While current therapeutic options do exist, such as chemotherapy or radiation, they both cause severe side effects by damaging healthy cells in addition to cancerous cells. Consequently, a primary objective in immune-oncology research is to develop an anti-cancer therapeutic that is more selective for cancer cells, minimizing damage to healthy tissue, and reducing side effects. Curcumin, the active compound found in turmeric, has been discovered to induce apoptosis only in cancerous cells. To deliver the payload of curcumin to the phospholipid bilayer, a derivative was created by synthesizing an activated NHS ester, allowing it to bind to the surface lysines found on a pentraxin. A pentraxin is a 5-member protein ring that is part of the innate immune system, serving as a protein chassis. By utilizing a naturally occurring protein, the chances of the human body rejecting treatment will be reduced. Bound to the curcumin pentraxin conjugate is a VHH antibody engineered to bind the Kv10.1 ion-gated channel. This ion-gated channel is highly expressed in cancerous cells and is rarely expressed in regular cells, making it an effective target. The curcumin derivative was synthesized with a 27.6% yield, confirmed using analytical methods. Protein expression in mammalian cells was achieved but yielded low amounts, indicating a need for optimization. Preliminary conclusions support the proof of concept; however, further testing will be necessary. These factors, when combined, could potentially create an effective anti-cancer therapeutic.
Awards (1)
- Drug, Chemical & Associated Technologies Association (DCAT): DCAT First Prize
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2016
Novel Selection of Enzymes Loaded in Mesoporous Nanoparticle Carrier Engineered to Selectively Target Cancer Cells Using Aptamer
ISEF · 2015
Development of a Novel Near-Infrared Fluorescent Theranostic Anticancer Prodrug
ISEF · 2024
Designing Drugs by Artificial Intelligence: Novel Curcuminoids for the Treatment of Papillary Renal Cell Carcinoma Type II (PRCC2)
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair